Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/15/25
End: 12/31/28
Due: 12/31/29
Phase: N/A
Priority: Normal
Start: 01/19/24
End: 01/31/26
Due: 01/31/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer | NCT07027514 | Ankyra Therapeutics, Inc | user2@example.com | None | 2025-08-15 | 2028-12-31 | 2029-12-31 | - | - | 2025-07-14 |
| Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors | NCT06171750 | Ankyra Therapeutics, Inc | user2@example.com | None | 2024-01-19 | 2026-01-31 | 2027-01-31 | - | - | 2025-07-14 |